Ottevanger, R.; van Beugen, S.; Evers, A.W.M.; Willemze, R.; Vermeer, M.H.; Quint, K.D.
Quality of Life in Cutaneous T-cell Lymphoma Patients Receiving Mogamulizumab: Important Factors to Consider. Cancers 2023, 15, 32.
https://doi.org/10.3390/cancers15010032
AMA Style
Ottevanger R, van Beugen S, Evers AWM, Willemze R, Vermeer MH, Quint KD.
Quality of Life in Cutaneous T-cell Lymphoma Patients Receiving Mogamulizumab: Important Factors to Consider. Cancers. 2023; 15(1):32.
https://doi.org/10.3390/cancers15010032
Chicago/Turabian Style
Ottevanger, Rosanne, Sylvia van Beugen, Andrea W. M. Evers, Rein Willemze, Maarten H. Vermeer, and Koen D. Quint.
2023. "Quality of Life in Cutaneous T-cell Lymphoma Patients Receiving Mogamulizumab: Important Factors to Consider" Cancers 15, no. 1: 32.
https://doi.org/10.3390/cancers15010032
APA Style
Ottevanger, R., van Beugen, S., Evers, A. W. M., Willemze, R., Vermeer, M. H., & Quint, K. D.
(2023). Quality of Life in Cutaneous T-cell Lymphoma Patients Receiving Mogamulizumab: Important Factors to Consider. Cancers, 15(1), 32.
https://doi.org/10.3390/cancers15010032